New data show midkine expression is heightened in small cell lung cancer, suggesting the growth factor may be an important ...

The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

Over the past decade, a better understanding of SCLC biology has enabled its classification into four subtypes on the basis of the distinct expression of specific transcription factors: ASCL1 (SCLC-A) ...

However, recent data suggests that analyzing the activity of certain proteins called transcription factors (TF) may help distinguish SCLC subtypes. Unfortunately, methods to study these TF profiles ...

Defining a new lung cancer subtype: Atypical small cell carcinoma. Small cell lung cancer (SCLC) is relatively rare to begin with, accounting for 10% to 15% of all lung cancers, according to the ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...

Small cell lung cancer (SCLC) often metastasizes to the brain and has poor prognosis. SCLC subtypes distinguished by expressing transcriptional factors ASCL1 or NEUROD1 have been identified. This ...

Limited-Stage SCLC Gets a New Standard of Care With Consolidation Durvalumab — Median OS was 55.9 months in the durvalumab group compared with 33.4 months in the placebo group ...